Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Palladio Biosciences Inc.
Headquarters: Horsham, PA, United States of America
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | Aug 17, 2023
Emerging Company Profile
How Abcuro is targeting specific T cells to treat a rare muscle-wasting disease
Crossovers back company in $155M round to advance KLRG1 program for inclusion body myositis
BioCentury | Jun 12, 2023
Deals
Seeking high-value drugs, Novartis adds kidney franchise in $3.2B Chinook takeout
Biotech’s later-stage candidates give pharma two chances at a blockbuster, starting with IgA nephropathy indication amid rising competition
BioCentury | Dec 1, 2021
Management Tracks
Grauer becomes CMO at Federation Bio
Plus: LabGenius, 23andMe, Vifor, Immunovia, Forma and more
BioCentury | Feb 16, 2021
Emerging Company Profile
Medicxi, blue chip investors launch Centessa with $250M to take asset-centric companies further
Emerging Company Profile: newco to bring asset-centricity to pharma scale
BioCentury | Sep 25, 2020
Finance
Palladio seeks to position Orphan kidney therapy as safer alternative with $20 million series B
Palladio will use its $20 million series B round to determine for investors and potential partners where exactly its autosomal dominant polycystic kidney disease (ADPKD) therapy lixivaptan will fit on
BioCentury | Mar 19, 2020
Management Tracks
Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more
BioCentury | Oct 11, 2019
Company News
Management tracks: Chan leaving FDA’s China office; plus Galera, Aridis and Palladio
BioCentury | Oct 3, 2019
Product Development
Kidney is the new liver: why kidney indications are coming into sharp focus
Investors and pharmas see big opportunities in the kidney, based on progress at both ends of the drug development spectrum
Items per page:
1 - 10 of 12